Parkinson’s disease
TARDBP
TDP-43
atypical parkinsonism
genetics
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
08
2022
accepted:
12
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Aggregates of TAR DNA-binding protein of 43 kDa (TDP-43) represent the pathological hallmark of most amyotrophic lateral sclerosis (ALS) and of nearly 50% of frontotemporal dementia (FTD) cases but were also observed to occur as secondary neuropathology in the nervous tissue of patients with different neurodegenerative diseases, including Parkinson's disease (PD) and atypical parkinsonism. Mutations of Direct DNA sequencing of Four In this study we provide further insight into the clinical phenotypic heterogeneity associated with
Sections du résumé
Background
UNASSIGNED
Aggregates of TAR DNA-binding protein of 43 kDa (TDP-43) represent the pathological hallmark of most amyotrophic lateral sclerosis (ALS) and of nearly 50% of frontotemporal dementia (FTD) cases but were also observed to occur as secondary neuropathology in the nervous tissue of patients with different neurodegenerative diseases, including Parkinson's disease (PD) and atypical parkinsonism. Mutations of
Methods
UNASSIGNED
Direct DNA sequencing of
Results
UNASSIGNED
Four
Conclusion
UNASSIGNED
In this study we provide further insight into the clinical phenotypic heterogeneity associated with
Identifiants
pubmed: 36247987
doi: 10.3389/fnagi.2022.1020948
pmc: PMC9557978
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1020948Informations de copyright
Copyright © 2022 Tiloca, Goldwurm, Calcagno, Verde, Peverelli, Calini, Zecchinelli, Sangalli, Ratti, Pezzoli, Silani and Ticozzi.
Déclaration de conflit d'intérêts
AR received research funding from AriSLA. VS received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb Srl, and Novartis Pharma AG. He receives or has received research support from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, and Frontiers in Neurology. NT received compensation for consulting services and/or speaking activities from Amylyx Pharmaceuticals, Zambon Pharma AG, and Italfarmaco. He received research funding from the Italian Ministry of Health and AriSLA. He is Associate Editor for Frontiers in Aging Neuroscience. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Neurobiol Aging. 2012 May;33(5):1016.e9-17
pubmed: 21943958
Ann Neurol. 2008 Apr;63(4):535-8
pubmed: 18288693
Neurobiol Aging. 2009 Aug;30(8):1329-31
pubmed: 18068872
Int J Biol Sci. 2011 Mar 04;7(2):234-43
pubmed: 21448284
Rejuvenation Res. 2010 Oct;13(5):509-17
pubmed: 20645878
Neurogenetics. 2013 May;14(2):161-6
pubmed: 23546887
J Biol Chem. 2017 Jun 23;292(25):10600-10612
pubmed: 28487370
Nucleic Acids Res. 2017 Jun 2;45(10):6177-6193
pubmed: 28335005
Neurobiol Aging. 2011 Dec;32(12):2327.e1-5
pubmed: 21803454
Hum Mol Genet. 2009 Sep 15;18(18):3353-64
pubmed: 19515851
Hum Mutat. 2009 Apr;30(4):688-94
pubmed: 19224587
Ann Neurol. 2009 Apr;65(4):470-3
pubmed: 19350673
Neurogenetics. 2011 Aug;12(3):203-9
pubmed: 21667065
Eur J Neurol. 2009 Jun;16(6):727-32
pubmed: 19236453
Amyotroph Lateral Scler. 2010;11(1-2):223-7
pubmed: 19714537
Ann Neurol. 2013 Jul;74(1):20-38
pubmed: 23686809
Neurobiol Aging. 2021 Nov;107:168-173
pubmed: 34175147
Neurobiol Aging. 2013 May;34(5):1517.e1-3
pubmed: 23062702
PLoS One. 2008 Jun 11;3(6):e2450
pubmed: 18545701
Neurobiol Aging. 2014 Dec;35(12):2882.e7-2882.e12
pubmed: 25123918
Neuron. 2013 Aug 7;79(3):416-38
pubmed: 23931993
Front Aging Neurosci. 2022 Jun 27;14:917706
pubmed: 35832068
Neurobiol Aging. 2014 May;35(5):1212.e7-1212.e10
pubmed: 24325798
J Neurol. 2013 Feb;260(2):454-7
pubmed: 22923257
Parkinsonism Relat Disord. 2013 Mar;19(3):312-5
pubmed: 23231971
Neurobiol Aging. 2012 Aug;33(8):1846.e1-4
pubmed: 22398199
Clin Genet. 2012 Feb;81(2):172-8
pubmed: 21418058
Nat Genet. 2008 May;40(5):572-4
pubmed: 18372902
CNS Neurol Disord Drug Targets. 2010 Jul;9(3):285-96
pubmed: 20406182
Neurobiol Aging. 2011 Nov;32(11):2096-9
pubmed: 20031275
Neurobiol Aging. 2018 Nov;71:265.e9-265.e14
pubmed: 29895397
Science. 2008 Mar 21;319(5870):1668-72
pubmed: 18309045
Clin Genet. 2012 Jul;82(1):83-7
pubmed: 21651514
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Nat Rev Neurol. 2010 Apr;6(4):211-20
pubmed: 20234357
Nat Rev Neurol. 2016 Mar;12(3):175-85
pubmed: 26891767
Neurobiol Dis. 2018 Jul;115:167-181
pubmed: 29630989
Hum Mutat. 2013 Jun;34(6):812-26
pubmed: 23559573
Arch Neurol. 2009 Feb;66(2):281-2
pubmed: 19204172
PLoS One. 2014 Aug 04;9(8):e103644
pubmed: 25090004
J Neurol Neurosurg Psychiatry. 2011 May;82(5):587-8
pubmed: 20959352
JAMA Neurol. 2020 Mar 1;77(3):377-387
pubmed: 31860007
J Neurol. 2013 Jan;260(1):85-92
pubmed: 22752089
Hum Mutat. 2009 Nov;30(11):E974-83
pubmed: 19655382
Lancet. 1993 Oct 23;342(8878):1016-8
pubmed: 8105264
J Neurol Sci. 2018 Jul 15;390:209-211
pubmed: 29801890
Arch Neurol. 2011 May;68(5):594-8
pubmed: 21220647
Mol Cell Biol. 2011 Mar;31(5):1098-108
pubmed: 21173160
Amyotroph Lateral Scler. 2012 Jan;13(1):155-7
pubmed: 21830990